Novel Variant Identified in the Enhancer Region of Host Transcription Factor, BRN3A, is a Significant Risk Factor for HPV-Induced Uterine Cervix Cancer.
International Journal Of Molecular And Cellular Medicine
Prakash, Anand A; Das Purkayastha, Biswa Pratim BP; Srivastava, Shikha S; Chaturvedi, Sunanda S; Ali, Akhtar A; Aggarwal, Dau Dayal DD; Roy, Jagat Kumar JK
Perspectives of Therapeutic Drug Monitoring of Biological Agents in Non-Infectious Uveitis Treatment: A Review.
Pharmaceutics
Busto-Iglesias, Manuel M; Rodríguez-Martínez, Lorena L; Rodríguez-Fernández, Carmen Antía CA; González-López, Jaime J; González-Barcia, Miguel M; de Domingo, Begoña B; Rodríguez-Rodríguez, Luis L; Fernández-Ferreiro, Anxo A; Mondelo-García, Cristina C
Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors.
Rmd Open
Weitz, Jeffrey I JI; Szekanecz, Zoltán Z; Charles-Schoeman, Christina C; Vranic, Ivana I; Sahin, Burak B; Paciga, Sara A SA; Wang, Zhenyu Z; Hyde, Craig C; Martin, David A DA
Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels.
Annals Of Hematology
Lewandowski, Krzysztof K; Kanduła, Zuzanna Z; Gniot, Michał M; Paczkowska, Edyta E; Nawrocka, Paulina Maria PM; Wojtaszewska, Marzena M; Janowski, Michał M; Mariak, Magdalena M; Handschuh, Luiza L; Kozlowski, Piotr P
The longitudinal dynamics and natural history of clonal haematopoiesis.
Nature
Fabre, Margarete A MA; de Almeida, José Guilherme JG; Fiorillo, Edoardo E; Mitchell, Emily E; Damaskou, Aristi A; Rak, Justyna J; Orrù, Valeria V; Marongiu, Michele M; Chapman, Michael Spencer MS; Vijayabaskar, M S MS; Baxter, Joanna J; Hardy, Claire C; Abascal, Federico F; Williams, Nicholas N; Nangalia, Jyoti J; Martincorena, Iñigo I; Campbell, Peter J PJ; McKinney, Eoin F EF; Cucca, Francesco F; Gerstung, Moritz M; Vassiliou, George S GS
Cytokine pathway variants modulate platelet production: IFNA16 is a thrombocytosis susceptibility locus in humans.
Blood Advances
Gnatenko, Dmitri V DV; Liu, Zhaoyan Z; Hearing, Patrick P; Sohn, Sook-Young SY; Hu, Yetao Y; Falanga, Anna A; Wu, Song S; Malone, Lisa E LE; Zhu, Wei W; Bahou, Wadie F WF
JAK2 Variant Signaling: Genetic, Hematologic and Immune Implication in Chronic Myeloproliferative Neoplasms.
Biomolecules
Torres, Dania G DG; Paes, Jhemerson J; da Costa, Allyson G AG; Malheiro, Adriana A; Silva, George V GV; Mourão, Lucivana P de Souza LPS; Tarragô, Andréa M AM
Is Polymorphism in the Apoptosis and Inflammatory Pathway Genes Associated With a Primary Response to Anti-TNF Therapy in Crohn's Disease Patients?
Frontiers In Pharmacology
Walczak, Michal M; Lykowska-Szuber, Liliana L; Plucinska, Marianna M; Stawczyk-Eder, Kamila K; Zakerska-Banaszak, Oliwia O; Eder, Piotr P; Krela-Kazmierczak, Iwona I; Michalak, Michal M; Zywicki, Marek M; Karlowski, Wojciech M WM; Szalata, Marlena M; Dobrowolska, Agnieszka A; Slomski, Ryszard R; Skrzypczak-Zielinska, Marzena M
Coexistence of gain-of-function JAK2 germ line mutations with JAK2V617F in polycythemia vera.
Blood
Lanikova, Lucie L; Babosova, Olga O; Swierczek, Sabina S; Wang, Linghua L; Wheeler, David A DA; Divoky, Vladimir V; Korinek, Vladimir V; Prchal, Josef T JT
Polymorphisms in the Toll-Like Receptor and the IL-23/IL-17 Pathways Were Associated with Susceptibility to Inflammatory Bowel Disease in a Danish Cohort.
Plos One
Bank, Steffen S; Andersen, Paal Skytt PS; Burisch, Johan J; Pedersen, Natalia N; Roug, Stine S; Galsgaard, Julied J; Ydegaard Turino, Stine S; Brodersen, Jacob Broder JB; Rashid, Shaista S; Kaiser Rasmussen, Britt B; Avlund, Sara S; Bastholm Olesen, Thomas T; Hoffmann, Hans Jürgen HJ; Andersen Nexø, Bjørn B; Sode, Jacob J; Vogel, Ulla U; Andersen, Vibeke V
Sporadic hemangioblastomas are characterized by cryptic VHL inactivation.
Acta Neuropathologica Communications
Shankar, Ganesh M GM; Taylor-Weiner, Amaro A; Lelic, Nina N; Jones, Robert T RT; Kim, James C JC; Francis, Joshua M JM; Abedalthagafi, Malak M; Borges, Lawrence F LF; Coumans, Jean-Valery JV; Curry, William T WT; Nahed, Brian V BV; Shin, John H JH; Paek, Sun Ha SH; Park, Sung-Hye SH; Stewart, Chip C; Lawrence, Michael S MS; Cibulskis, Kristian K; Thorner, Aaron R AR; Van Hummelen, Paul P; Stemmer-Rachamimov, Anat O AO; Batchelor, Tracy T TT; Carter, Scott L SL; Hoang, Mai P MP; Santagata, Sandro S; Louis, David N DN; Barker, Fred G FG; Meyerson, Matthew M; Getz, Gad G; Brastianos, Priscilla K PK; Cahill, Daniel P DP
Genetic association between germline JAK2 polymorphisms and myeloproliferative neoplasms in Hong Kong Chinese population: a case-control study.
Bmc Genetics
Koh, Su Pin SP; Yip, Shea Ping SP; Lee, Kwok Kuen KK; Chan, Chi Chung CC; Lau, Sze Man SM; Kho, Chi Shan CS; Lau, Chi Kuen CK; Lin, Shek Ying SY; Lau, Yat Ming YM; Wong, Lap Gate LG; Au, Ka Leung KL; Wong, Kit Fai KF; Chu, Raymond W RW; Yu, Pui Hung PH; Chow, Eudora Y D EY; Leung, Kate F S KF; Tsoi, Wai Chiu WC; Yung, Benjamin Y M BY
The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population.
Bmc Medical Genetics
Ohyashiki, Junko H JH; Yoneta, Masayuki M; Hisatomi, Hisashi H; Iwabuchi, Tamiko T; Umezu, Tomohiro T; Ohyashiki, Kazuma K
The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection?
The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms.
Haematologica
Olcaydu, Damla D; Rumi, Elisa E; Harutyunyan, Ashot A; Passamonti, Francesco F; Pietra, Daniela D; Pascutto, Cristiana C; Berg, Tiina T; Jäger, Roland R; Hammond, Emma E; Cazzola, Mario M; Kralovics, Robert R
A multidisciplinary investigation of a polycythemia vera cancer cluster of unknown origin.
International Journal Of Environmental Research And Public Health
Seaman, Vincent V; Dearwent, Steve M SM; Gable, Debra D; Lewis, Brian B; Metcalf, Susan S; Orloff, Ken K; Tierney, Bruce B; Zhu, Jane J; Logue, James J; Marchetto, David D; Ostroff, Stephen S; Hoffman, Ronald R; Xu, Mingjiang M; Carey, David D; Erlich, Porat P; Gerhard, Glenn G; Roda, Paul P; Iannuzzo, Joseph J; Lewis, Robert R; Mellow, John J; Mulvihill, Linda L; Myles, Zachary Z; Wu, Manxia M; Frank, Arthur A; Gross-Davis, Carol Ann CA; Klotz, Judith J; Lynch, Adam A; Weissfeld, Joel J; Weinberg, Rona R; Cole, Henry H
The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms.
Blood
Jones, Amy V AV; Campbell, Peter J PJ; Beer, Philip A PA; Schnittger, Susanne S; Vannucchi, Alessandro M AM; Zoi, Katerina K; Percy, Melanie J MJ; McMullin, Mary Frances MF; Scott, Linda M LM; Tapper, William W; Silver, Richard T RT; Oscier, David D; Harrison, Claire N CN; Grallert, Harald H; Kisialiou, Aliaksei A; Strike, Paul P; Chase, Andrew J AJ; Green, Anthony R AR; Cross, Nicholas C P NC
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.
Nature Genetics
Jones, Amy V AV; Chase, Andrew A; Silver, Richard T RT; Oscier, David D; Zoi, Katerina K; Wang, Y Lynn YL; Cario, Holger H; Pahl, Heike L HL; Collins, Andrew A; Reiter, Andreas A; Grand, Francis F; Cross, Nicholas C P NC